Gaush Meditech Ltd (FRA:F7Y)
Germany
· Delayed Price · Currency is EUR 0.985
-0.005 (-0.51%)
Last updated: Dec 4, 2025, 8:22 AM CET
Gaush Meditech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 1,439 | 1,428 | 1,406 | 1,254 | 1,298 | 962.08 | Upgrade
|
| Revenue Growth (YoY) | 6.82% | 1.58% | 12.16% | -3.42% | 34.94% | -13.06% | Upgrade
|
| Cost of Revenue | 768.17 | 774.43 | 721.64 | 632.54 | 696.61 | 525.91 | Upgrade
|
| Gross Profit | 671.28 | 653.96 | 684.6 | 621.25 | 601.61 | 436.17 | Upgrade
|
| Selling, General & Admin | 390.15 | 378.36 | 378.21 | 333.94 | 320.99 | 250.9 | Upgrade
|
| Research & Development | 86.68 | 78.42 | 52.88 | 41.09 | 23.51 | 3.14 | Upgrade
|
| Other Operating Expenses | 30.24 | 31.61 | 0.2 | 19.19 | 13.8 | 1.57 | Upgrade
|
| Operating Expenses | 507.06 | 488.39 | 431.3 | 394.21 | 358.3 | 255.61 | Upgrade
|
| Operating Income | 164.22 | 165.58 | 253.3 | 227.03 | 243.32 | 180.56 | Upgrade
|
| Interest Expense | -26.66 | -36.71 | -50.61 | -42.68 | -83.53 | -3.08 | Upgrade
|
| Interest & Investment Income | 3.18 | 3.18 | 6.58 | 4.68 | 2.02 | 3.13 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.41 | - | 15.56 | -172.47 | 61.82 | 18.32 | Upgrade
|
| Other Non Operating Income (Expenses) | 16.23 | 19.52 | 18.8 | 16.43 | 13.97 | 12.73 | Upgrade
|
| EBT Excluding Unusual Items | 159.37 | 151.56 | 243.63 | 32.99 | 237.6 | 211.66 | Upgrade
|
| Gain (Loss) on Sale of Investments | 4.88 | 3.72 | 3.96 | -307.42 | -375.51 | -62.36 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.15 | -0.67 | -0.05 | -0.14 | Upgrade
|
| Pretax Income | 164.25 | 155.29 | 247.74 | -275.09 | -137.96 | 149.16 | Upgrade
|
| Income Tax Expense | 66.76 | 66.76 | 74.82 | 77.62 | 53.61 | 50.62 | Upgrade
|
| Earnings From Continuing Operations | 97.49 | 88.52 | 172.91 | -352.71 | -191.57 | 98.54 | Upgrade
|
| Minority Interest in Earnings | 4.41 | 3.87 | 0.61 | 3.09 | 1.12 | 0.83 | Upgrade
|
| Net Income | 101.89 | 92.39 | 173.52 | -349.62 | -190.45 | 99.37 | Upgrade
|
| Net Income to Common | 101.89 | 92.39 | 173.52 | -349.62 | -190.45 | 99.37 | Upgrade
|
| Net Income Growth | 12.34% | -46.75% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 147 | 148 | 148 | 97 | 96 | 105 | Upgrade
|
| Shares Outstanding (Diluted) | 147 | 148 | 148 | 97 | 96 | 105 | Upgrade
|
| Shares Change (YoY) | -0.77% | -0.14% | 52.69% | 1.16% | -9.03% | -3.28% | Upgrade
|
| EPS (Basic) | 0.69 | 0.63 | 1.17 | -3.61 | -1.99 | 0.94 | Upgrade
|
| EPS (Diluted) | 0.69 | 0.63 | 1.17 | -3.61 | -1.99 | 0.94 | Upgrade
|
| EPS Growth | 13.36% | -46.68% | - | - | - | - | Upgrade
|
| Free Cash Flow | 125.16 | 93.12 | 214.11 | 189.03 | 137.94 | 128.23 | Upgrade
|
| Free Cash Flow Per Share | 0.85 | 0.63 | 1.45 | 1.95 | 1.44 | 1.22 | Upgrade
|
| Dividend Per Share | 0.282 | 0.282 | 0.998 | - | - | - | Upgrade
|
| Dividend Growth | -71.77% | -71.77% | - | - | - | - | Upgrade
|
| Gross Margin | 46.63% | 45.78% | 48.68% | 49.55% | 46.34% | 45.34% | Upgrade
|
| Operating Margin | 11.41% | 11.59% | 18.01% | 18.11% | 18.74% | 18.77% | Upgrade
|
| Profit Margin | 7.08% | 6.47% | 12.34% | -27.88% | -14.67% | 10.33% | Upgrade
|
| Free Cash Flow Margin | 8.70% | 6.52% | 15.23% | 15.08% | 10.63% | 13.33% | Upgrade
|
| EBITDA | 225.07 | 222.68 | 306.06 | 271.91 | 287.2 | 185.27 | Upgrade
|
| EBITDA Margin | 15.64% | 15.59% | 21.77% | 21.69% | 22.12% | 19.26% | Upgrade
|
| D&A For EBITDA | 60.86 | 57.1 | 52.76 | 44.87 | 43.88 | 4.71 | Upgrade
|
| EBIT | 164.22 | 165.58 | 253.3 | 227.03 | 243.32 | 180.56 | Upgrade
|
| EBIT Margin | 11.41% | 11.59% | 18.01% | 18.11% | 18.74% | 18.77% | Upgrade
|
| Effective Tax Rate | 40.64% | 42.99% | 30.20% | - | - | 33.94% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.